Spyre Therapeutics Files 8-K on Accountant Change
Ticker: SYRE · Form: 8-K · Filed: Mar 6, 2025 · CIK: 1636282
| Field | Detail |
|---|---|
| Company | Spyre Therapeutics, Inc. (SYRE) |
| Form Type | 8-K |
| Filed Date | Mar 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, auditor-change, financial-statements
TL;DR
Spyre Therapeutics (formerly Aeglea) filed an 8-K for auditor change and financial docs.
AI Summary
On February 28, 2025, Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) filed an 8-K report. The filing primarily concerns changes in the registrant's certifying accountant and includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Waltham, MA.
Why It Matters
This filing indicates a change in the company's auditor, which can sometimes signal shifts in financial reporting or internal controls.
Risk Assessment
Risk Level: low — The filing is routine and primarily concerns administrative changes and financial reporting, not a material event impacting operations or strategy.
Key Players & Entities
- Spyre Therapeutics, Inc. (company) — Registrant
- Aeglea BioTherapeutics, Inc. (company) — Former Name
- February 28, 2025 (date) — Date of earliest event reported
- Waltham, MA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report changes in the registrant's certifying accountant and to include financial statements and exhibits.
What was Spyre Therapeutics, Inc.'s former name?
Spyre Therapeutics, Inc.'s former name was Aeglea BioTherapeutics, Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 28, 2025.
Where are Spyre Therapeutics, Inc.'s principal executive offices located?
Spyre Therapeutics, Inc.'s principal executive offices are located at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 6, 2025 regarding Spyre Therapeutics, Inc. (SYRE).